Purpose We have previously demonstrated that prostate tumors that highly express Bcl-2 are not only more tumorigenic, but also more angiogenic than low Bcl-2 expressing tumors. Observed increased rates of angiogenesis are likely due to the secretion of multiple factors from the tumor cells.
Introduction
Previously, we have demonstrated the concomitant overexpression of Bcl-2 and VEGF in PC-3 human prostate xenograft tumors, the latter of which may have been responsible for an associated increased rate of angiogenesis [1] . We also observed that the murine neovasculature in Bcl-2 expressing PC-3 xenografts also expressed high Bcl-2 levels. Given the known anti-apoptotic role of Bcl-2, its expression may render endothelial cells resistant to conventional cancer therapeutics. Although the role of Bcl-2 in endothelial cell survival has been investigated, the induction mechanisms and the molecular changes associated with Bcl-2 expression are poorly understood.
In this study, we show that VEGF can induce Bcl-2 expression in human microvascular endothelial cells (HMVEC) , and that this is associated with increased proliferation and resistance to apoptosis. This suggests that VEGF can act as a positive mediator linking Bcl-2 expression in both epithelial and endothelial cells. Better understanding of the molecular mechanisms involved in this link would be beneWcial because therapies that can interfere with Bcl-2 expression and/or VEGF function may have synergistic eVects on tumor progression by limiting the growth and survival of cancerous tumors expressing Bcl-2.
Materials and methods

Cell lines and culture
HUVEC and HMVEC cells (Cambrex, Wakeville, MD) were grown in supplemented EGM-2-MV media (without the addition of VEGF) (Lonza, Pittsburg, PA). Prostate cancer cell lines, PC-3-Bcl-2 and PC-3-Neo [2] , were maintained in supplemented DMEM (Mediatech, Inc. Herndon, VA) and grown in standard conditions.
Reagents
Protein kinase C (PKC) inhibitor, RO31-8220 (2.76 mg/ml) was purchased from Calbiochem (San Diego, CA) and suspended in sterile H 2 O. Phosphoinistol 3 kinase (PI3K) inhibitor, LY294002 (4 mM); p38 inhibitor, SB203580 (1 mg/ml); ERK inhibitor, PD98059 (5 mg/ml); and actinomycin D (1 mg/ml) were purchased from Calbiochem (San Diego, CA) and dissolved in DMSO before use. mTOR inhibitor, rapamycin (1 mM) was purchased from Alexis Biochemical (San Diego, CA) and dissolved in DMSO. Bevacizamub (25 mg/ml) was purchased from Besse Medical (West Chester, OH) and diluted in sterile PBS.
In vitro proliferation assay HUVEC and HMVEC cells were seeded in 96-well plates at a density of 5 £ 10 3 cells per well and treated with PBS, VEGF at concentrations ranging from 0 to 50 ng/ml or conditioned media from PC-3-Neo or PC-3-prostate cancer cells. After 24 h, 100 l of 1 mg/ml MTT (Sigma-Aldrich, St. Louis, MO) solution was added and analyzed as previously described [1] .
Quantitative PCR analysis of RNA HUVEC and HMVEC cells were seeded in 12-well plates at 5 £ 10 4 cells per well and treated with DMEM media without serum, conditioned media from PC-3-Bcl-2 cells, conditioned media from PC-3-Neo cells, DMEM media with VEGF (50 ng/ml) or DMEM media with VEGF (50 ng/ml) and bevacizamub (0.125 mg/ml) for 6 h prior to RNA isolation. Similarly, only HMVEC cells were treated with control, VEGF (50 ng/ml) or VEGF in addition to RO31-8220 (10 M), rapamycin (30 nM), LY294002 (100 nM), SB203580 (10 M), or PD98059 (50 M) for 6 h prior to RNA isolation. At the completion of the experiments, RNA was isolated and analyzed as previously described [3] .
Western blot analysis HMVEC cells were seeded in 12-well plates at 5 £ 10 4 cells per well and treated with control, VEGF (50 ng/ml) or conditioned media from PC-3-Neo or PC-3-Bcl-2 for 24 h. Immunoblotting was performed by Wrst incubating the proteins with primary antibodies against Bcl-2 and -tubulin (Santa Cruz Biotechnology, Santa Cruz, CA) and then with secondary antibody (Bio-Rad).
mRNA stability assay HMVEC cells were cultured in 12-well plates at 5 £ 10 4 cells per well with or without VEGF supplemented media (50 ng/ml) for 6 h, and then with the transcription inhibitor actinomycin D (1 g/ml). At time points ranging from 0 to 24 h, cells were harvested and total RNA isolated. Bcl-2 transcripts in HMVEC were measured as described above.
Statistical analysis
DiVerences between experimental groups were analyzed for statistical signiWcance using Student's t tests. A value of P < 0.05 was considered signiWcant.
Gene expression microarray analysis
Duplicate cultures of HMVEC cells were seeded in 6-well plates at a density of 1 £ 10 5 cells per well for 24 h. PC-3-Bcl-2 and PC-3-Neo prostate cancer cells were seeded in 75 cm 2 Xask at a density of 5 £ 10 5 cells per well for 24 h. In two-thirds of the HMVEC cultures, media was decanted and PC-3-Bcl-2 or PC-3-Neo media was added to the HMVEC cultures for 6 h, whereas the other third of the cultures received naïve DMEM. Total RNA was extracted from each of the samples and prepared for hybridization according to the GeneChip Expression Analysis Technical Manual (AVymetrix, Santa Clara, CA) and as previously described [4] . Signals from signiWcantly regulated genes were z-transformed with a mean of 0 and standard deviation of 1, and hierarchical clustered using Cluster and TreeView program [5] . Biological network relationships among signiWcantly regulated genes were explored using Pathway Studio (Ariadne Genomics, Inc., Rockville, MD) and ResNet mammalian database [6] .
Results and discussion
VEGF induces endothelial cell proliferation in vitro
As observed in previous in vitro studies [7, 8] , treatment with exogenous VEGF resulted in a signiWcant enhancement 
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of cellular proliferation in HMVEC cells in a dose-dependent manner (Fig. 1a) . Previously, our group demonstrated that PC-3-Bcl-2 cells expressed and secreted signiWcantly more VEGF compared to PC-3-Neo cells [9] . With this in mind, next we demonstrated a signiWcant increase in cellular proliferation in HMVEC cells cultured in conditioned media obtained from PC-3-Bcl-2 cells compared to PC-3-Neo cells (P = 0.01) (Fig. 1a) . This suggests that VEGF secreted by PC-3-Bcl-2 prostate cancer cells can stimulate endothelial cellular proliferation and promote angiogenesis.
In line with the proliferation eVect described above, Bcl-2 upregulation was also induced in HMVEC cells subjected to exogenous VEGF (Fig. 1b) . This eVect has also been demonstrated by other investigators [8] . Similarly, conditioned culture media obtained from PC-3-Bcl-2 prostate cancer cells induced HMVEC cells to over-express Bcl-2 (Fig. 1b) . To conWrm the contribution of VEGF in the induction of Bcl-2 expression in HMVEC cells subjected to exogenous VEGF or conditioned media from Bcl-2 expressing cells, a monoclonal antibody to VEGF, bevacizumab, was added to the culture media used to treat HMVEC cells. The addition of bevacizumab signiWcantly inhibited the induction of Bcl-2 mRNA by exogenous VEGF and PC-3-Bcl-2 conditioned media (Fig. 1b) . Because of this phenomenon, only HMVEC cells were used for subsequent experiments.
VEGF stimulation of HMVEC cells results in the stabilization in Bcl-2 mRNA Having shown that VEGF induces Bcl-2 transcript levels, we investigated whether the eVect may be mediated through stabilization of Bcl-2 mRNA by performing a mRNA half-life analysis. Analysis of the PCR data shows that HMVEC Bcl-2 mRNA had a half-life of 60 min, and that VEGF treatment extended the half-life to 105 min, *P < 0.05 (Fig. 2a) .
Inhibition of mTOR, PKC, ERK, and PI3K signaling pathways suppresses VEGF-mediated Bcl-2 expression in endothelial cells
Based on the literature, we hypothesized that upon binding with its receptor, VEGF may activate other signaling molecules in the following pathways to induce Bcl-2 expression: PKC [10] , MAPK (ERK1/2) [11] , stress-activated protein kinase-2, p38 MAPK [12] , or PI3K [11] . To assess whether these speciWc pathways were involved in the VEGF-mediated induction of Bcl-2 in HMVEC, we analyzed Bcl-2 transcript induction by quantitative RT-PCR in cells stimulated with VEGF treatment and one of Wve molecular inhibitors to key biologic pathways, namely mTOR, PKC, PI3K, ERK, and p38. As previously illustrated, VEGF stimulation of HMVEC cells resulted in upregulation of Bcl-2 (Fig. 2b) . Both LY294002 and RO-31-8220 suppressed VEGF-induced Bcl-2 expression by over 90%. Impressively, rapamycin was able to completely block Bcl-2 upregulation by VEGF in HMVEC cells. This is the Wrst report to show that mTOR is pivotal to VEGF-mediated cellular eVects associated with endothelial Bcl-2 expression. PD98059 suppressed Bcl-2 expression by approximately 40%, whereas the one other inhibitor assessed, SB 203580 had no eVect on VEGF-mediated Bcl-2 expression. It appears that HMVECs can utilize multiple molecular pathways (mTOR, PKC, PI3K, and ERK, Fig. 2b ) to regulate Bcl-2 expression. This redundancy illustrates the importance of Bcl-2 expression in growth and survival of tumor endothelial cells.
The importance of the redundancy that ensures survival of the endothelial cells can have immense therapeutic Fig. 3 Functional association of gene clusters and network of genes related to exposure of HMVEC cells to conditioned media from Bcl-2 expressing tumors. RNA extracted from duplicate cultures of treated HMVEC cells was hybridized to AVymetrix U133 Plus 2.0 arrays. Genes absent in all samples were removed from the data set. Due to the small replicate number, local-pooled-error (LPE) test was performed to identify diVerentially expressed genes between conditions PC-3-Bcl-2 media versus DMEM media and PC-3-Bcl-2 media versus PC-3-Neo media. Genes with bonferroni corrected P value < 0.001 and at least twofold change were considered signiWcantly regulated. Of the 54,613 targets on the array, the expression of 629 genes were signiWcantly diVerentially expressed (greater than a twofold change and P < 0.001) between PC-3-Bcl-2 stimulated cells and unstimulated cells and 313 genes were signiWcantly diVerentially expressed between PC-3-Bcl-2 stimulated cells and PC-3-Neo stimulated cells. Two-way hierarchical clustering was performed on the 629 (PC-3-Bcl-2 vs. control) genes and the 313 (PC-3-Bcl-2 vs. PC-3-Neo) genes in order to group together genes with expression patterns that were similar in response to treatment. Table 1 Genes regulated by Bcl-2 tumoral environment on the HMVEC endothelial cell line (P < 0.001)
Functional groups of genes were assigned using gene-association Wles from the GO Consortium and by GenMapp and Kegg pathway analysis. Full gene list is available at http://genomics. signiWcance. This redundancy may play a role in radiation resistance or androgen independent prostate cancer. The importance of this redundancy is evident in the recent Xourish in the clinical development of over 30 targeted protein kinase inhibitors designed to inhibit angiogenesis, tumor growth and progression [13, 14] . SpeciWcally, Imatinib mesylate [15] , Sorafenib [16] , Sunitinib malate [17] , and Temsirolimus [18] have demonstrated eYciency in solid tumors including renal cell carcinoma.
Bcl-2 expression in HMVEC cells is associated with a unique gene expression proWle
To acquire insight into the broader transcriptome of endothelial cells in the microenvironment of Bcl-2 expressing tumor cells, gene expression proWles of HMVEC (stimulated with PC-3-Bcl-2 conditioned media), HMVEC (stimulated with PC-3-Neo conditioned media), and HMVEC (unconditioned media) cells were evaluated using microarray technology. Using the within-clustering correlation >0.9 as threshold, two distinct clusters were identiWed for each group and a total of 142 genes were identiWed as being similarly altered in both groups (Fig. 3a) . Of this list of 142 genes, 20 genes of interest are illustrated in Table 1 along with distribution of diVerentially expressed genes (Fig. 3b) . Potential biological links between the regulated genes were revealed by analysis of the 142 gene list using Pathway Studio (Fig. 3c) . Adhesion of tumor cells to endothelium via cell-adhesion molecules is a key step in tumor growth and metastasis. Intercellular adhesion molecule 1 (ICAM-1) is an endothelium protein known to bind tumor cells. In addition, cells binding to ICAM-1 can auto-upregulate endothelial ICAM-1 expression at the leading edge of the tumor, promoting release of other chemoattractants that can sustain the growth of tumors [19] . One such chemoattractant is chemokine ligand 2 (CCL2), recently found to be a prominent regulator of prostate cancer growth and metastasis [20] . CCL2 was also upregulated in our model. Researchers have shown that intratumoral injection of CCL2 induces eVective interaction between monocytes and endothelial cells in the peritumoral area, accompanied by the upregulation of ICAM-1 [21] .
CXCL8 belongs to the superfamily of chemokines that possess an assortment of proinXammatory eVects. CXCL8 is produced by a wide range of cells, including tumor cells [22] . CXCL8 expression can modulate angiogenesis and invasiveness and/or extracellular matrix remodeling in the tumor microenvironment and cellular CXCL8 levels have been correlated with VEGF levels [23] . CXCL8 interacts directly with many of the same genes as ICAM-I (Fig. 3c) illustrating considerable biological overlap between CXCL8 and ICAM-I. Recent work by Zeitlin and others demonstrated in an in vivo model that targeting endothelial Bcl-2 with small molecule inhibitors resulted in inhibition of the production of potent pro-angiogenic (e.g., CXCL1 and CXCL8) molecules with a marked reduction in angiogenesis [24] .
The other key hub revolves around the gene STAT1 (signal transducers and activators of transcription 1) which was downregulated in stimulated HMVEC cells. STAT1 has been previously shown to inhibit angiogenesis when induced by interferon gamma [23] , and serves as a potent inhibitor of cell growth and as a promoter of apoptosis. STAT1 is negatively regulated by Janus kinase 3 [25] , which we found to be upregulated in the Bcl-2 stimulated endothelial cells. Limited data exist on a role for STAT-1 in angiogenesis; however, it has been demonstrated that siRNA targeting of STAT-1 is associated with reduced IFN-gamma and increased VEGF secretion, leading to retardation of angiogenesis [26] .
While it is intriguing to suggest that the increase in VEGF secreted by PC-3-Bcl-2 stimulates endothelial cellular proliferation and that bevacizumab possess the ability to block this stimulation, we cannot excluded that multiple other factors may be involved (e.g., bFGF, CXCL8). Thus more research is needed to better elucidate other factors that may be involved in this critical event.
Further analysis into the molecular pathways mediating VEGF-induced Bcl-2 expression in endothelial cells will identify critical mechanisms that might be valuable targets for anti-angiogenic therapies, but more importantly, strategies designed to overcome the survival advantage aVorded by Bcl-2 and VEGF could provide doubly eVective treatments that target both tumor cells and the supporting endothelial cells essential to tumor progression.
ConXict of interest statement
None.
